Calypte und die Zeit nach AIDS2004 in Bangkok

 

 

 

 

 

PLEASANTON, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it will begin shipping its HIV-1 BED Incidence EIA test (Incidence Test) this week. The first shipment is destined for South Africa, and the Company currently has initial orders for approximately 12,000 tests worldwide. Shipments to China and Brazil should commence in the coming weeks.

In April 2004, the Company announced that it had been granted a worldwide non-exclusive license by the United States Centers for Disease Control and Prevention (CDC) to commercially manufacture and sell a unique test that was developed by the CDC in order to help epidemiologists and researchers estimate the spread of HIV-1 infection. The Incidence Test employs epitopes from three subtypes of HIV-1 known as B, E, and D, the test can be used on all of the major subtypes of HIV-1 that are found around the world.

Unlike most HIV antibody tests that are designed as a screening test to determine if an individual has been exposed to HIV-1, the Incidence Test is a population research tool intended to be used on populations already known to be infected in order to determine how many of the infections occurred in the last 6 months. Such information may give policy makers and program managers valuable insights regarding the success of their prevention programs and how best to allocate resources.

The test is believed to be valuable for targeting populations with a high incidence of HIV infections for interventional studies and/or vaccine trials. It can also be used to evaluate the effectiveness of intervention efforts by showing either a negative or positive change in the incidence of infections following the intervention effort. The Calypte HIV-1 BED Incidence EIA test is for use in research to estimate the incidence of HIV-1 in a population. It is not for use as a diagnostic test.

Dr. Richard George, President and CEO of Calypte said, "We have successfully transferred the manufacturing process for the Incidence Test from the CDC to Calypte in very short order, and that is a great accomplishment for our staff. We are encouraged by the reception that we have received from HIV researchers who have expressed strong interest in this product, and I believe that this test will find utility in many countries around the world. Workshops are currently being planned to train people to use the test by various major public health organizations both internationally and in the United States. Calypte is supporting those efforts and believes that it will result in wider use of the tests. For some of these researchers, the Incidence Test will fe their first exposure to Calypte, and we anticipate that their experience with the innovation of the Incidence Test will fuel an interest in our other HIV assays as well."

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 Incidence EIA as well as tests that can determine HIV antibody status without the need for blood. Calypte is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

    Company Contact:                  Investor Relations Contact:
    Richard George, CEO               Tim Clemensen,
    (925) 730-7200                    Rubenstein Investor Relations
    email: rgeorge@calypte.com        Phone: (212) 843-9337
                                      email: tclemensen@rubensteinir.com

SOURCE Calypte Biomedical Corporation
10/25/2004
Web site: http://www.calypte.com



P.S Hat sich jemand erkundigt was so ein Test Kit kostet.

12000 * ?  =


Gruß

C.O
 

Es ist traurig wenn viele jetzt meinen auszusteigen ist es sicherlich traurig aber ich persönlich werde bis zur meinem erfolg wo ich per. fest überzeugt bin das es kommt drin bleiben..


No Risk No Fun


Gruß

C.O
 

Calypte Biomedical Announces Third Quarter and Nine-Month Financial Results


PLEASANTON, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced financial results for the third quarter and nine-months ended September 30, 2004. Revenue for the quarter was $361,000, versus revenue of $897,000 for the comparable period in 2003. The net loss attributable to common stockholders for the quarter decreased 48% to $3.8 million, or $0.02 per common share, compared to a net loss of $7.3. million, or $0.11 per common share for the three months ended September 30, 2003. The net loss for the third quarter of 2004 and 2003 included approximately $0.1 million and $4.3 million, respectively, in non-cash charges that were primarily related to the grants of common stock and options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.

For the nine months ended September 30, 2004, revenues were $2.2 million, versus revenues of $2.4 million for the same period last year. The net loss attributable to common stockholders decreased by 49% to $11.1 million, or $0.07 per common share, compared to a net loss of $21.58 million, or $0.75 per common share for the nine months ended September 30, 2003. The net loss for the nine months ended September 30, 2004 and 2003 included approximately $1.0 million and $12.0 million, respectively, in non-cash charges that were primarily related to the grants of common stock and options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.

The decrease in revenues for the quarter is primarily attributable to the limited purchases by all three of the company's large domestic insurance laboratory customers. During the second quarter of 2004, these labs purchased additional inventory in anticipation of the shutdown of the Company's California facility and consolidation of operations in its Rockville, Maryland facility and the Company believes that these labs had sufficient inventory during the third quarter.

Richard George, CEO of Calypte stated, "We have advanced our strategic initiatives this quarter to include obtaining the rights to a new patent pending rapid diagnostic test platform and sample applicator technology for the worldwide professional and OTC human in-vitro diagnostic testing markets. We have also entered into a worldwide, non-exclusive licensing agreement with Bio-Rad Laboratories for patents relating to the Human Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is the exclusive licensee of Institut Pasteur of Paris, France, under the HIV-2 patents. With the prevalence in the world of the HIV-2 virus, this license is intended to allow Calypte's rapid tests to diagnose a broader population of HIV-infected individuals. We believe that these milestones have positioned us to now focus on our mission of creating international and domestic sales."

Calypte management will host a conference call at 5:00 p.m. Eastern Time today to discuss and answer questions regarding the Company's third quarter financial results as well as provide an update on the Company's current activities.

The call can be accessed in the U.S. by dialing 800-901-5241 and outside of the U.S. by dialing 617-786-2963 and entering conference identification number 47706706. The conference call will also be webcast live at http://www.calypte.com. An audio replay of the call will be available until November 28, 2004, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The conference identification number is 87730958. The replay will also be available at http://www.calypte.com until November 28, 2004.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 Incidence EIA as well as tests that can determine HIV antibody status without the need for blood. Calypte is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser- developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, demand for the Company's products, the Company's success in designing and developing products, the Company's research and development costs, the length of development and product acceptance cycles, the amount that the Company invests in new business opportunities and the timing of those investments, competition, the degree to which the Company enters into commercial agreements and strategic transactions and maintains and develops commercial relationships, foreign exchange risks, world events, international growth and expansion and changes in laws and regulations. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

    Company Contact:                   Investor Relations Contact:
    Richard Brounstein, CFO            Tim Clemensen,
    (925) 730-7200                     Rubenstein Investor Relations
    Email:  rbrounstein@calypte.com    Phone: 212-843-9337
                                       Email:  tclemensen@rubensteinir.com


                CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

                     CONSOLIDATED STATEMENTS OF OPERATIONS
                     (in thousands, except per share data)
                                   Unaudited

                                       Three Months Ended   Nine Months Ended
                                          September 30,        September 30,
                                          2004     2003      2004      2003

    Revenues:
      Product sales                        $361     $897    $2,242    $2,430

      Cost of product sales               2,095    1,750     5,088     4,714
        Gross Margin (Loss) on product
         sales                           (1,734)    (853)   (2,846)   (2,284)

    Other operating expenses:
      Research and development costs        509      304     1,623       953
      Selling, general and
       administrative costs               1,800    2,754     6,536    12,371

        Total other operating expenses    2,309    3,058     8,159    13,324

          Loss from operations           (4,043)  (3,911)  (11,005)  (15,608)

    Interest income (expense)
     (primarily non-cash for all
     periods except three months ended
     September 30, 2004)                     79   (3,282)     (451)   (6,054)
     Minority interest in consolidated
      joint venture                         156        -       346         -
    Other income (expense)                    6      (30)       25       174

          Loss before income taxes       (3,802)  (7,223)  (11,085)  (21,488)

    Income taxes                              -        -        (2)       (2)

          Net loss                       (3,802)  (7,223)  (11,087)  (21,490)

    Less dividends on mandatorily
     redeemable Series A
     preferred stock                          -      (30)        -       (90)

    Net loss attributable to common
     stockholders                       $(3,802) $(7,253) $(11,087) $(21,580)

    Net loss per share attributable to
     common stockholders
     (basic and diluted)                 $(0.02)  $(0.11)   $(0.07)   $(0.75)

    Weighted average shares used to
     compute net loss per share
     attributable to common stockholders
     (basic and diluted)                167,703   68,862   150,950    28,796


                 CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY

                        CONSOLIDATED BALANCE SHEET DATA
                                (in thousands)
                                   Unaudited

                                                 September 30,   December 31,
                                                      2004            2003

    Cash and cash equivalents                        $4,504          $5,084
    Working capital                                   1,366           2,865
    Total Assets                                     11,935           9,517
    Convertible notes and debentures,
     net of discount                                     30             868
    Other long term liabilities                         426             157
    Minority Interest in joint venture                 (290)             57
    Mandatorily redeemable Series A
     preferred stock                                  2,786           2,696
    Total stockholders' equity                        2,855             917

SOURCE Calypte Biomedical Corporation
10/28/2004
CONTACT: Richard Brounstein, CFO, +1-925-730-7200, rbrounstein@calypte.com; Investor Relations, Tim Clemensen, Rubenstein Investor Relations, +1-212-843-9337, tclemensen@rubensteinir.com, for Calypte Biomedical Corporation
Web site: http://www.calypte.com



Viel besser habe ich Persönlich die Zahlen Stand 30. September nicht erwartet.
Das Verschiffen wurde am 25. Oct. veröffentlich

Desweitere wird kommen



Gruß

C.O

 

...ihr könnt gerne weiterhin stur bleiben. einige ausser euch sehen es jetzt wenigstens ein und steigen aus. der rest kann sich gerne weiterhin von cataldo und co verprügeln lassen...

micha, wenn ich deine kommentare lese, dass die zahlen scheißegal sind, dann werfe ich mich weg....anderen sind die zahlen scheinabr nicht egal...

wie ich schon sagte, wenn ihr nicht verkauft, machen es die anderen und das geschieht.

auch son 1000 mal erwähnt. phantasie kann immer ur eine kurze zeit eine rolle spielen, aber nie über 3,5 jahre hinweg...

mal sehen, wo diese roßkur und götterdämmerung für einige noch hinführt.

ende des jahres seid ihr unter 0,20$....versprochen...

enigen besonders sturen und "sympathischen" unter euch kann ich nur sagen: ihr habt es wirklich nicht besser verdient. die fakten stehen sogar in den filings. man kann diese euch 1000 mal reinkopieren, einige wollen es einfach nicht begreifen. wer meint, immer wieder auf den herd packen zu müssen oder die hand gar erst gar nicht wegzuziehen, der kann zusehen, wie diese langsam verkohlt und das ist besonders schmerzhaft...


Time & Sales most recent  next page
Rec. Time Action Price Volume
12:18:32 PM Ask 0.28  5700  
12:18:22 PM Ask 0.28  8800  
12:16:58 PM Ask 0.28  10000  
12:16:46 PM Ask 0.28  8800  
12:15:26 PM Ask 0.28  10000  
12:15:08 PM Ask 0.28  8800  
12:13:42 PM Trade 0.28  7000  
12:13:42 PM Ask 0.28  10000  
12:11:22 PM Trade 0.28  200  
12:11:22 PM Ask 0.28  12700  
12:09:58 PM Trade 0.28  3000  
12:09:58 PM Ask 0.28  13000  
12:05:40 PM Trade 0.27  2000  
12:01:38 PM Trade 0.27  2000  
11:58:52 AM Bid 0.27  100800  
11:58:38 AM Bid 0.27  100900  
11:57:24 AM Bid 0.27  90900  
11:55:04 AM Ask 0.28  16000  
11:54:40 AM Bid 0.27  90800  


ihr seid heute aber nur noch schwach im minus...  

ein paar nette bildchen hier herein, wenn es euch hilft, euch selber weiterhin zu betrügen.

jedoch weiß ich, tief in euch hört ihr die stimme, die euch sagt, dass das "geschwür joelu" recht hat....auch meldet sich beim einen oder anderen das gewissen, warum man mich immer mit "pech und schwefel" überschüttet hat und nicht auf mich gehört hat...

naja, fegt eure scherben selber weg...von mir könnt ihr nicht erwarten, dass ich euch auch noch das kehrblech stelle...  

 

tumor ist, wenn man trotzdem lacht!  

wenn caly auf 0.00000000001 $ wäre, ich würde mich krumm lachen.
buchalterisch sind die bei mir seit dem moment auf 0 $ an dem ich sie gekauft habe. capischi mann?
das sind keine bundesobligationen, das ist ein mega-zock und nix anderes!!  

 

       
       

aber wie gesagt...
seltsam finde ich nur dass die keine nachrichten aus dem treff am freitag bringen..  

Geschwür bist, hast Du richtig erkannt !  

der Verkauf von 12000 HIV-1 BED Incidence EIA test (Incidence Test) war der Beginn,
andere werden folgen inklusive der Rapid- Tests.
Grüße an Alle Calys,Lucky

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

8 Tage im Karwendelgebirge geiles Wetter, super Aussicht von den Bergen aus und
kein Streß von allen.
Grüße Lucky

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

herliches stück deutschland. einfach nur schön.  

das sind 400 x 12000 = 4.800.000 Dollar

und das ist erst der Anfang !
Los auf mich einprügeln auf gehts !.

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

einprügeln? wir spielen doch im gleichen team!! :-)  

 

aber immerhin